Laman UtamaAUROPHARMA • NSE
add
Aurobindo Pharma Ltd
Tutup sebelumnya
₹1,103.40
Julat hari
₹1,104.00 - ₹1,137.50
Julat tahun
₹581.25 - ₹1,177.10
Permodalan pasaran
662.87B INR
Bilangan Purata
1.48J
Nisbah P/E
23.92
Hasil dividen
0.40%
Pertukaran utama
NSE
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (INR) | Dis 2023info | Perubahan T/T |
|---|---|---|
Hasil | 73.52B | 14.74% |
Perbelanjaan pengendalian | 30.23B | 5.46% |
Pendapatan bersih | 9.36B | 90.59% |
Margin untung bersih | 12.74 | 66.10% |
Pendapatan bagi setiap syer | 16.04 | 91.41% |
EBITDA | 14.59B | 64.96% |
Kadar cukai berkesan | 25.54% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (INR) | Dis 2023info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 71.49B | 10.47% |
Jumlah aset | — | — |
Jumlah liabiliti | — | — |
Jumlah ekuiti | 281.95B | — |
Syer tertunggak | 583.72J | — |
Harga kepada buku | 2.31 | — |
Pulangan pada aset | — | — |
Pulangan pada modal | 8.45% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (INR) | Dis 2023info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 9.36B | 90.59% |
Tunai daripada operasi | — | — |
Tunai daripada pelaburan | — | — |
Tunai daripada pembiayaan | — | — |
Perubahan bersih dalam tunai | — | — |
Aliran tunai bebas | — | — |
Perihal
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer. Wikipedia
Diasaskan
1986
Ibu pejabat
Tapak web
Pekerja
23,451
